Table 1 Pooled estimates of proportions for risk and benefit outcomes in studies evaluating the use of anticoagulant prophylaxis for venous thromboembolism in orthopedic surgery

All patients

Ximelagatran

3.274 (3.175, 3.372)

0.098

1.804 (1.722, 1.885)

0.082

LMWH

6.528 (6.357, 6.699)

0.171

2.208 (2.156, 2.260)

0.052

UFH

13.394 (12.862, 13.926)

0.532

2.494 (2.363, 2.625)

0.131

Warfarin

6.278 (6.092, 6.463)

0.186

1.778 (1.690, 1.867)

0.088

Fondaparinux

2.051 (1.957, 2.146)

0.094

5.113 (4.690, 5.536)

0.423

Placebo

21.019 (19.978, 22.060)

1.041

1.781 (1.651, 1.912)

0.130

Total hip replacement

Ximelagatran

3.401 (3.181, 3.621)

0.220

2.892 (2.683, 3.101)

0.209

LMWH

6.472 (6.293, 6.651)

0.179

2.151 (2.085, 2.216)

0.066

UFH

15.154 (14.446, 15.862)

0.708

2.813 (2.625, 3.001)

0.188

Warfarin

4.280 (4.083, 4.477)

0.197

2.229 (2.088, 2.371)

0.141

Fondaparinux

2.138 (2.009, 2.267)

0.129

6.033 (5.501, 6.566)

0.532

Placebo

24.726 (23.268, 26.184)

1.458

1.463 (1.299, 1.628)

0.164

Total knee replacement

Ximelagatran

3.100 (3.042, 3.158)

0.058

1.127 (1.095, 1.159)

0.032

LMWH

5.143 (5.010, 5.277)

0.134

1.605 (1.566, 1.644)

0.039

UFH

9.119 (8.803, 9.436)

0.316

0.943 (0.837, 1.050)

0.106

Warfarin

8.100 (7.879, 8.322)

0.221

0.822 (0.792, 0.852)

0.030

Fondaparinux

2.446 (2.288, 2.603)

0.158

2.128 (2.003, 2.252)

0.124

Placebo

14.833 (14.351, 15.314)

0.482

2.116 (1.911, 2.322)

0.205